ejpmr, 2020,7(11), 706-711

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

EFFECT OF DIPEPTIDYL PEPTIDASE 4 INHIBITOR DRUGS IN COMBINATION WITH OTHER MEDICINES IN TYPE 2 DIABETES MELLITUS (T2DM)

Suresh Chandra* and Komal Manwani

Pranveer Singh Institute of Technology, Kanpur-Agra-Delhi National Highway- 2, Bhauti, Kanpur, Uttar Pradesh, 209305.

***Corresponding Author: Suresh Chandra**

Assistant Professor, Pranveer Singh Institute of Technology, Kanpur-Agra-Delhi National Highway- 2, Bhauti, Kanpur, Uttar Pradesh, 209305.

Article Received on 21/09/2020 **Article Revised on 11/10/2020** **Article Accepted on 1/11/2020**

ABSTRACT

Dipeptidyl peptidase IV is a focal controller of insulin-animating hormones, glucagon-like peptides, and insulinotropic glucose-subordinate polypeptides. So it's a decent objective for type 2 DM. care, plasma decrease DPP IV protein adds to expanded inherent glucagon, for example, peptide-1, GIP action which at last outcomes in the potentiation of pancreatic islet insulin discharge and ensuing bringing down of blood glucose levels, HbA[1c], glucose emission, the advancement of liver glucose. One of the key objectives of diabetes care is to arrive at restorative methodologies for hemoglobin HbA[1c] and maintain a strategic distance from the inception or decline of a microvascular condition, investigating effectively the DPP IV inhibitor, for example, Sitagliptin and Vildagliptin. A few other novel DPP IV inhibitors are in the pipeline Unless some contraindications for metformin treatment is endorsed and if HbA[1c] targets are not reached after 3 months.several specialist class of drugs could be added in treatment for example, sulfonylurea, Thiazolidinediones, DPP IV inhibitor. Regardless of a wide scope of remedial choices, the accomplishment of HbA[1c] focuses on individuals with diabetes stays testing, with simply over half (52%) of diabetes patients accomplishing a typical HbA[1c] focus of < 7.0%. The present review reveals that the effect of DPP IV inhibitors, combined with other drugs and therapeutic advantages over GLP-1 based approach.

KEYWORDS: Diabetes2 Dipeptidyl Peptidase-4, Glucose-dependent, Polypeptide, Insulinotrophic, Glucagon-like Peptide-1, type 2 Diabetes Mallitus.

INTRODUCTION

DM is a largely spreading disease. The predominance of DM in the US is near 32 million and in the future, it will be increased, if present patterns endure, one out of three grown-ups could have diabetes by 2050.[1] Type 2 DM is caused by insulin obstruction & reformist β-cell dysfunction,[2] more than > 90% of cases diagnosed.[3] It was created in the relationship between constant hyperglycemia and microvascular difficulties create. Strict glycaemic control can assist with diminishing the danger of microvascular difficulties and right constant hyperglycemia on β-cells and insulin emission pathophysiological harmful. American Diabetes Association (ADA) rules depend on a bit by bit way to deal with glycaemic control.[4] A glaciated hemoglobin (HbA1c) focus of < 7 % is recommended for most grown-ups with T2DM. A point of < 6.5 % is suggested in patients who can deal with a more thorough HbA1c focus without extreme hypoglycemia or other antagonistic impacts. For patients with further developed illness, genuine co horrible conditions, or a background marked by extreme hypoglycemia, however, less severe glycaemic targets (>7 %) might be adequate. Metformin is the suggested pharmacological starting treatment for type 2 diabetes mellitus.[5] Metformin diminishes groupings of normal l and PP glucose by diminishing the creation of liver glucose and restoration of intestinal glucose and expanding the fringe blend and utilization of glucose.[6] At the point when utilized in the treatment of patients with type 2 DM as monotherapy, metformin decreased HbA1c by 1.4 %. Metformin additionally adds to weight reduction. The ADA suggests the expansion of a second pharmacologic specialist for patients taking metformin yet at the same time encountering hyperglycemia after ~3 months. New oral hypoglycaemic agents or insulin might be included if a patient doesn't come to the individualized HbA [1c] focus after another ~3 months. A combination of drugs with reciprocal systems of activity may help address the numerous basic broken glycemic control factors. The direction from ADA where specialists need to decide for the triple treatment regimens is flexible and even less prescriptive. Even though this features the importance of fitting pharmacological consideration to the necessities of a specific patient, this likewise underscores the trouble of restorative choices, owing to some degree to the wide range of open operators. Although the restorative profiles of conventional operators, for example, metformin,

sulfonylurea, and Thiazolidinediones (TZDs) are settled in single-drug therapy and combination regimens, extra some of the knowledge are required on the fresher specialists, inhibitors of DPP-IV or inhibitors of Na-glucose cotransport (SGLT2) as trial use keeps on expanding.

DPP-IV inhibitors are taken up consideration because of the incretin impact as a novel class of antihyperglycemic drugs. The most readily accessible specialist was Sitagliptin, vildagliptin, saxagliptin, linagliptin, and Alogliptin.[8] DPP-4 inhibitors accomplish glucose suppress by repressing the DPP-IV chemical which adds to the quick degradation of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-subordinate insulinotropic polypeptide (GIP), both delivered after food consumption and in this manner Glucose-decreasing movement by inciting insulin discharge and β-cells and hindering glucagon emission by glucose-subordinate pancreatic cells.[9] There are two significant impediments in the creation of against diabetic medications dependent on GIP, including quick degradation by the protein DPP-4 and extremely low incretin action in type 2 DM. GLP-1 is likewise quickly inactivated in the circulatory system by DPP-IV catalyst however its incretin impacts are still to a great extent kept up in patients with type 2 diabetes[10] Thus, in individuals with type 2 DM, DPP-IV inhibitors support glycaemic guideline in a glucose-subordinate way by restraining GIP and GLP-1 inactivation and afterward practicing their different organic exercises. DPP-IV restraint can likewise limit the emission of postprandial glucagon from pancreatic α cells and altogether increment cell mass, prompt little islets, and invigorate islet neogenesis.[11]

Dipeptidyl peptidase 4 inhibitors

DPP-IV inhibitors evade gastrointestinal incretin glucagon-like GLP-1 and glucose-subordinate insulinotropic polypeptide (GIP) corruption, bringing about expanded GLP-1 and GIP glycaemic guideline. A few past investigations have surveyed the adequacy and security of DPP-IV inhibitors and insulin blend treatment, including methodical audits and meta-examinations dependent on discoveries from randomized controlled preliminaries (RCTs). These are anyway just restricted information contrasting DPP-IV4 inhibitors and other antihyperglycemic operators in a mix with insulin, especially straight on correlations, and no fundamental audits or Meta examinations have been distributed. The objective of our pertinent methodical audit and meta-investigation was accordingly to evaluate the viability and wellbeing of DPP-IV inhibitors related to insulin treatment contrasted with fake treatment or other antihyperglycemic operators. Generally speaking, the clinical atherosclerosis impacts of DPP-IV inhibitors stay questionable, particularly in patients with beginning phase vascular brokenness. Past investigations inspecting endothelial capacity have reported heterogeneous impacts of DPP-IV inhibitors in both healthy[12] volunteers and Type2 DM. patients.[13-17] These heterogeneous discoveries can be because of appropriate techniques and differences in the considered populaces. What's more, contrasts in glucose control between the examination arms could have kept firm ends from being drawn about the pleiotropic impacts of the hindrance of DPP-IV versus impacts coming about because of hyperglycemia decrease, which is proposed to support endothelial function.[18] In this investigation, we assessed the momentary impacts of DPP-IV inhibitor linagliptin contrasted with a functioning comparator (sulphonylurea, Glimepiride) and wrong treatment on estimations of full scale and miniature vascular endothelial capacity in solid patients with straight forward T2D who were illustrative of an essential anticipation populace (for example had no history of prior cardiovascular malady).[19]

Action mechanism of dpp-4 inhibitors

The part of incretin hormone reactions and inadequacies in T2DM Glucagon-like peptide 1 (GLP-1) and glucose-subordinate insulinotropic polypeptide (GIP) keeps on being important to major incretin hormones, basic for glucose-subordinate insulin emission. GLP-1 moreover acts to hinder the arrival of glucagon, incite expansion of β-cells, and moderate gastric purging. Under typical physiological conditions, the exopeptidase DPP-IV enzyme rapidly separates GLP-1 and GIP. Regardless of whether GLP-1 discharge is likewise diminished in patients with Type 2 DM is blended proof. In any case, it is conjectured that the reduced incretin impact is expected to a limited extent to a diminished postprandial GLP-1 reaction and a diminished insulinotropic reaction.[20] DPP-IV inhibitors specifically repress the DPP-IV compound and along these lines delay GLP-1 and GIP corruption and increment their circulatory concentrations. DPP-IV inhibitors improve the affectability of β-cells to glucose in a glucose-subordinate way, increment insulin emission and decline glucagon secretion. In vivo outcomes additionally, show guarded and remedial properties, exhibited with treatment by expanded β-cell mass and morphology.[21] Clinical preliminaries have demonstrated the adequacy of DPP-IV inhibitor single-drug therapy in Type 2 DM patients, and circuitous examinations of individual specialists show practically identical efficacy. Importantly, DPP-IV inhibitors are related to generally safe hypoglycemia, weight loss, and an uncommon event of critical antagonistic responses. Some DPP-4 inhibitors are as follows:

A. Alogliptin

Alogliptin has been given with a combination of other drugs. When combined with the metformin, Alogliptin fundamentally alters HbA1c and fasting plasma glucose (FPG) from pattern to more than 25 weeks versus placebo treatment.[22] Diminishes in standard FPG with Alogliptin was additionally measurably fundamentally higher contrasted and Glipizide add-on starting at weeks 15 and 25 and stretching out more than 105 weeks,[23] individually. Tests Glycemic Dual treatment with Alogliptin was related with considerable upgrades in

HbA1c contrasted with glyburide monotherapy and mathematical enhancements in auxiliary glycemic measures[24] in a different trial of Alogliptin setting glyburide 10 mg for 26 weeks. In the triple oral treatment routine, either added to the foundation metformin as double treatment with Pioglitazone or added to the foundation pioglitazone and metformin,[25] important helpful impacts on glycemic boundaries were related with Alogliptin oral treatment regimens comparative with double treatment arms at 26 weeks. The study brings about patients getting insulin with or without metformin or in patients accepting pioglitazone with or without metformin or sulfonylurea additionally indicated that Alogliptin was added to generously help HbA1c by week 4 and held glycemic guideline by week 26.[26-30]

B. Linagliptin

Linagliptin has been demonstrated to be compelling in diminishing HbA1c and FPG from benchmark when managed for 24 weeks being taken care of by patients as an underlying mix treatment with metformin.[31] A comparative example for improved glycemic boundaries was likewise seen in patients proceeding with metformin with linagliptin as starting blend treatment with Pioglitazone or as an extra therapy.[32-33] Contrasted with the Glimepiride add-on with metformin,[34] metformin add-on linagliptin delivered comparative changes in HbA1c and FPG at 2 years. Linagliptin an extra to metformin in addition to sulfonylurea or TZD altogether upgraded fundamental glycemic adequacy discoveries at 24 weeks in triple blend treatment, with disparities from double treatment arriving at measurable essentialness.[35-36] Comparable changes in pattern HbA1c and FPG at 24 weeks with the expansion of linagliptin as a new specialist.[37] A further audit of patients delineated by foundation drug demonstrated that, in patients taking foundation metformin, sulfonylurea with or without metformin or insulin alone or in combination,[38] the expansion in HbA1c from benchmark accomplished factual hugeness with add-on linagliptin versus placebo treatment.

C. Saxagliptin

Saxagliptin improved HbA1c and FPG from the gauge in three individual 24-week preliminaries when utilized as an underlying blend treatment with metformin in treatment-innocent patients or when utilized as an extra to setting metformin.[39] Furthermore, as an underlying blend or extra treatment, more patients came to HbA1c < 7 percent with saxagliptin.[40-41] Extra saxagliptin was not substandard compared to HbA1c decrease from the gauge at 52 weeks in a relative report against add-on glipizide to metformin.[42] Double treatment including saxagliptin and a sulfonylurea or TZDadditionally exhibited significantly improved adequacy results.[43-44] Extra saxagliptin in blend with insulin with or without metformin demonstrated considerable changes in HbA1c from a pattern at 24 weeks.While with the expansion of saxagliptin, there was a pattern towards progress in FPG and the extent of patients accomplishing HbA1c < 7 %, contrasts from fake treatment didn't accomplish factual essentialness.[45] Saxagliptin fundamentally diminished HbA1c from the standard when applied to metformin and sulfonylurea for 24 weeks contrasted and placebo treatment add-on even though the move from the benchmark in FPG didn't show a significant distinction between classes, increase the number of patients acquired HbA1c < 7% with triple treatment with saxagliptin.[46]

D. Sitagliptin

Sitagliptin was appeared to generously help HbA1c and FPG from the standard at 24 weeks as an underlying blend treatment with metformin or extra to metformin and to expand the extent of patients accomplishing HbA1c < 7%.[47-48] Contrasted with the Glipizide to metformin add-on, add-on sitagliptin to metformin demonstrated no inadequacy at 52 weeks to limit HbA1c from standard.[49] Moreover, double treatment with Sitagliptin applied to Pioglitazone for more than 20 weeks fundamentally improved glycemic results contrasted with monotherapy with Pioglitazone. In various multiple treatment regimens, sitagliptin has been examined. Results demonstrated that the expansion of sitagliptin with or without metformin to Glimepiride considerably improved HbA1c and FPG from benchmark at 24 weeks and expanded the extent of patients accomplishing HbA1c by < 7%.The expansion of Sitagliptin for 24 weeks was appeared to essentially support glycemic brings about consistent insulin patients with or without metformin comparative with fake treatment, including HbA1c, FPG, and the extent of patients accomplishing HbA1c < 7%. Comparable and considerable changes in glycemic viability were shown in a different report with the 24-week expansion of Sitagliptin consistent Pioglitazone and metformin.

Safety and tolerability of dpp-iv inhibitors in combination therapy

The safer profile of multiple treatment protocols utilizing a DPP-IV inhibitor was near that seen in placebo treatment and no significant safety issues were found. The impartial or useful impact on weight was reliably seen in these occurrences. Indeed, even an impartial weight impact was seen when DPP-IV inhibitor treatment was applied to the insulin-containing regimens. Little weight increases, an archived symptom of sulfonylurea and TZDs, were seen when these OADs included DPP-IV inhibitor regimens. DPP-IV inhibitors add to hypoglycemia. A low rate of hypoglycemia has been dependably seen when joined with metformin or TZD, and when joined with insulin, the rate of hypoglycemia has commonly been near that seen with inactive drug treatment added substances.

DISCUSSION

This treatment is helpful for patients who can't endure metformin beginning, mix treatment with a DPP-IV inhibitor, and a TZD or an SGLT2 inhibitor likewise be gainful. The recent approaches assess the solution of

multi-treatment regimens exhibit an additional advantage with the incorporation of a DPP-IV inhibitor or SGLT2 inhibitor as a third specialist contrasted and double treatment arms. By and large, the safety parameter of DPP-IV inhibitors or SGLT2 blocker in a combination with other hypoglycaemic operators was commonly more known impacts of individual monotherapy segments. Current information recommends that both classes of medicine produce more safety and efficacy. An epic treatment approach is the utilization of a DPP-IV inhibitor with an SGLT2 inhibitor in triple mix treatment. Blend treatment regimens of these medications inferable from their exhibited clinical adequacy, a low rate of hypoglycemia, and an impartial or valuable impact on weight. The examination additionally demonstrated that the glucose-bringing down activities of a DPP-IV inhibitor in addition to an SGLT2 inhibitor might be reciprocal, instead of added substance. This review suggests that DPP-IV inhibitors be utilized carefully, and don't recommend for those patients who have a cardiovascular illness. Seeing from the progressing and huge scope Cardiovascular Research has demonstrated that β cell brokenness happens prior and more seriously than recently accepted. Research has indicated that patients with initial conditions of DM have just lost ~ 48% of their β -cell volume and patients with debilitated glucose resistance may have lost near about 78% of β - cell work. Although the specific instrument by which insulin opposition prompts β-cell disappointment is obscure, starting early therapy may help forestall reformist β -cell decrease. There is early proof, in vivo, that demonstrates a helpful impact on β-cell mass and morphology with DPP-IV inhibitors and a gainful impact on β- cell work with SGLT2 inhibitors. In blend with another Type 2 DM prescription with a synergistic component of activity, there is potential to defer or perhaps forestall the regular movement of β-cell disappointment and produce a sturdy therapy impact.

CONCLUSION

Clinical examinations show that patients with Type2DM uphold the viability, safety, and tolerability of double and multi blend treatment regimens including a DPP-IV inhibitor or potentially an SGLT2 inhibitor. Step by step approach remains the standard treatment like mix treatment early may help that find out in the early-stage different site of dysfunction and helpful in the treatment of future complication. Various research has exhibited the safety and tolerance properties of starting blend treatment are effective in patients. For patients with T2DM with deficient glycemic control with double treatment, the expansion of a DPP-IV inhibitor and additionally an SGLT2 inhibitor is clinically helpful as a new treatment module.

ACKNOWLEDGEMENT

The author wishes to thank Pranveer Singh Institute of Technology, Bhauti -Kanpur, Uttar Pradesh, India, for carrying out practical work and providing literature reviewing support for this study.

REFERENCES

1. American Diabetes Association. Fast facts: data and statistics about diabetes. Alexandria, VA: American Diabetes Association, 2013.
2. DeFronzo RA. From the triumvirate to the „ominous octet": a new paradigm for the treatment of type 2 diabetes mellitus. Clinical Diabetology, 2009; 10(3): 101-28.
3. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, Atlanta, GA: US Department of Health and Human Services, 2014.
4. American Diabetes Association. Standards of medical care in diabetes-Diabetes Care, 2015; 38: 1–94.
5. Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, Dagogo-Jack S, Davidson M, Einhorn D, Garvey W, Grunberger G. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm consensus statement. Endocrine Practice, 2013; 19(Supplement 2): 1-48.
6. Glucophage (metformin). Full Prescribing Information, Bristol-Myers Squibb Company. Princeton, 2009.
7. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine, 1995; 333(9): 541-9.
8. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010; 30(5): 463-84.
9. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes care, 2003; 26(10): 2929-40.
10. Wilding JP, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. Bmj, 2011; 342.
11. Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsbøll T, Knop FK. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013; 56(5): 965-72.
12. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of Clinical Endocrinology & Metabolism, 2001; 86(8): 3717-23.
13. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes, 2003; 52(2): 380-6.
14. Nisal K, Kela R, Khunti K, Davies MJ. Comparison of efficacy between incretin-based therapies for type

2 diabetes mellitus. BMC medicine, 2012; 10(1): 152.
15. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes, Obesity and Metabolism, 2009; 11: 9-17.
16. Poucher SM, Cheetham S, Francis J, Zinker B, Kirby M, Vickers SP. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, obesity and metabolism, 2012; 14(10): 918-26.
17. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Therapy, 2014; 5(1): 1-41.
18. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. International journal of clinical practice, 2009; 63(1): 46-55.
19. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes, Obesity and Metabolism, 2014; 16(12): 1239-46.
20. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes, Obesity and Metabolism, 2009; 11(2): 167-76.
21. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism, 2014; 16(7): 613-21.
22. Rosen stock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with Alogliptin and Pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care, 2010; 33: 2406–8.
23. Haak T, Meinicke T, Jones R, Weber S, Eynatten MV, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 2012; 14(6): 565-74.
24. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 2011; 13(7): 653-61.
25. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 2011; 13(1): 65-74.
26. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet, 2012; 380(9840): 475-83.
27. Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D'Agostino D, Woerle HJ. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabetic medicine, 2014; 31(12): 1505-14.
28. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study 1. Diabetic Medicine, 2011; 28(11): 1352-61.
29. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a≥ 52-week randomized, double-blind study. Diabetes care, 2013; 36(12): 3875-81.
30. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. The Lancet, 2013; 382(9902): 1413-23.
31. DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, Chen RS, Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care, 2009; 32(9): 1649-55.
32. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism, 2009; 11(6): 611-22.
33. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes research and clinical practice, 2011 ; 94(2): 217-24.

34. Göke B, Gallwitz B, Eriksson J, Hellqvist Å, Gause-Nilsson I, D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. International journal of clinical practice, 2010; 64(12): 1619-31.
35. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. CV181-040 Investigators: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract, 2009; 63(9): 1395-406.
36. Hollander P, Li J, Allen E, Chen R. CV181-013 Investigators: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009; 94(12): 4810-9.
37. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Current medical research and opinion, 2012; 28(4): 513-23.
38. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes, Obesity and Metabolism, 2014; 16(5): 443-50.
39. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes care, 2006; 29(12): 2638-43.
40. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes care, 2006; 29(12): 2638-43.
41. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, compared with the sulfonylurea, Glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab, 2007; 9: 194–205.
42. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Study S. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical therapeutics, 2006; 28(10): 1556-68.
43. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity and Metabolism, 2007; 9(5): 733-45.
44. Vilsbøll T, Rosenstock J, Yki-Järvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2010; 12(2): 167-77.
45. Fonseca V, Staels B, Morgan II JD, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and its Complications, 2013; 27(2): 177-83.
46. Scheen AJ. A review of gliptins in 2011. Expert opinion on pharmacotherapy, 2012; 13(1): 81-99.
47. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006; 368(9548): 1696-705.
48. Althage MC, Ford EL, Wang S, Tso P, Polonsky KS, Wice BM. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. Journal of Biological Chemistry, 2008; 283(26): 18365-76.
49. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 2003; 52(3): 741-50.